The Filing Desk

Novocure

NVCR · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

NVCR · Last close · November 13, 2026
$11.83
Value Novocure yourself

Novocure's revenue rose 8.3% to $655 million in fiscal 2025. Its operating margin was −23.5%, up from −28.2% a year earlier. Free cash flow was −$76 million. The diluted share count rose 3.4%.

NovoCure Limited Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001645113-26-000017 Updated
Revenue
$655M
8.3%
Operating margin
−23.5%
4.7 pts
Net income
−$136M
 
Free cash flow
−$76M
 
Return on capital
−33.0%
5.7 pts
Market cap
$1.4B
Nov 13 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Novocure does

Novocure is an oncology company that makes a medical device for cancer. Its technology, Tumor Treating Fields, uses electric fields applied through the skin to exert physical forces that the company says kill cancer cells. Patients wear the device, which is sold under the Optune name.

It has three commercial devices. Optune Gio is approved in the United States for glioblastoma, an aggressive brain cancer, and in the European Union, the United Kingdom, Japan, Canada and other countries. Optune Lua is approved for metastatic non-small cell lung cancer and, in the US, for malignant pleural mesothelioma. Optune Pax is approved in the US for locally advanced pancreatic cancer. Novocure is also seeking approval for new uses, such as brain metastases from lung cancer.

Its revenue comes from patients using its devices, and it relies on payment from insurers and Medicare. Novocure says it has had only occasional and intermittent operating profits and has a history of substantial operating losses.

Its biggest risks, as it describes them

  • It has only occasional operating profits and a history of substantial losses.
  • Doctors, patients and insurers may not accept its products as fast as it expects.
  • It may not secure or keep the coverage, billing codes and Medicare payment rates it needs.
  • It depends on single-source suppliers for some components.
  • Its clinical studies could be delayed, including by slow patient enrollment.
From Novocure's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Novocure lost money in fiscal 2025: a net loss of $136 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments20911524116494
Debt incl. finance leases56256656997195
Net debt (negative means net cash)353450328−67102
Net debt to EBITDA—————
Debt to equity1.4x1.3x1.6x0.3x0.6x
Interest coverage−5.0x−11.0x−47.5x−14.6x−6.9x
Current ratio7.5x7.0x5.8x1.5x2.9x
Quick ratio7.4x6.8x5.6x1.4x2.7x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Novocure's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Novocure shares on the open market, and 7 insiders sold $2.9 million.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Jun 4, 2026Frank X LeonardChief Executive OfficerSold34,273$17.93$614,515Form 4
Jun 2, 2026Jeryl L HillemanDirectorSold2,945$15.77$46,443Form 4
Mar 5, 2026Mukund ParavasthuChief Operating OfficerSold43,246$13.77$595,497Form 4
Mar 4, 2026Uri WeinbergChf Medical and Innovation OfrSold6,412$13.31$85,344Form 4
Mar 4, 2026Frank X LeonardChief Executive OfficerSold5,607$13.31$74,629Form 4
Mar 4, 2026Mukund ParavasthuChief Operating OfficerSold5,377$13.31$71,568Form 4
Mar 4, 2026Michal Nath PuriChief Human Resources OfficerSold1,100$13.31$14,641Form 4
Mar 3, 2026William F DoyleExecutive Chairman, DirectorSold71,887$12.98$933,086Form 4
Mar 2, 2026Frank X LeonardChief Executive OfficerSold7,232$13.49$97,560Form 4
Mar 2, 2026Uri WeinbergChf Medical and Innovation OfrSold3,272$13.33$43,616Form 4
Mar 2, 2026Mukund ParavasthuChief Operating OfficerSold408$13.49$5,504Form 4
Feb 27, 2026Frank X LeonardChief Executive OfficerSold9,734$13.66$132,966Form 4
The latest 12 of 16 trades. Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score1 of 95 of 94 of 9
Rule of 40−25.0%7.4%−3.3%
Altman Z''1.21−1.67−2.29
Accruals ratio−11.4%−11.9%−8.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassFail
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailPassFail
Revenue rose relative to assetsFailPassPass
F-score1 of 95 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Novocure side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
NovocureFY258.3%−23.5%−11.6%−33.0%—4
TransMedics GroupFY2537.1%17.9%22.1%27.5%−0.2x7Compare
UFP TechnologiesFY2519.5%15.3%—14.4%1.0x5Compare
iRhythmFY2526.2%−7.7%4.6%−12.4%—5Compare
BioventusFY25−0.9%9.5%12.7%11.1%2.5x8Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue83177248351494535538509605655
Revenue growth150.5%113.6%40.1%41.6%40.7%8.2%0.5%−5.3%18.8%8.3%
Gross profit37121168263388420423381468488
Research and development42385179132201206223210224
Operating income−115−39−34−130−44−90−233−170−154
Net income−132−62−64−720−58−92−207−169−136
Diluted EPS (US$)−1.54−0.70−0.69−0.070.18−0.56−0.88−1.95−1.56−1.22
Diluted shares (millions)86889297109103105106108112
Cash flow
Cash from operations−108−33−227998331−73−26−49
Capital expenditure67710152421274327
Free cash flow−113−40−91684599−100−69−76
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation222740527695107116160105
Balance sheet at fiscal year end
Cash and short-term investments1007914117723520911524116494
Debt incl. finance leases00014943056256656997195
Total assets2822653404791,0521,1401,1921,1461,241804
Total liabilities140152228262576729750784881464
Shareholders' equity142114112218476410441362360340
Margins and ratios
Gross margin44.2%68.6%67.7%74.8%78.5%78.5%78.6%74.8%77.3%74.5%
Operating margin−139.1%−22.2%−13.6%−0.3%6.2%−8.3%−16.6%−45.7%−28.2%−23.5%
Net margin−159.1%−34.8%−25.6%−2.1%4.0%−10.9%−17.2%−40.6%−27.9%−20.8%
Free cash flow margin−136.7%−22.9%−3.5%4.6%17.0%10.9%1.8%−19.7%−11.4%−11.6%
Rule of 40 (growth + FCF margin)13.9%90.7%36.7%46.2%57.8%19.2%2.3%−25.0%7.4%−3.3%
Return on capital−104.4%−79.7%—−0.9%7.1%−4.9%−8.6%−23.3%−27.4%−33.0%
Return on equity−67.1%−48.2%−56.3%−4.4%5.7%−13.2%−21.7%−51.5%−46.7%−38.9%
Return on assets−44.7%−22.5%−21.0%−1.8%2.6%−5.3%−7.9%−17.7%−14.1%−13.3%
Net debt to EBITDA———−3.7x4.9x—————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Novocure's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Novocure.